Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Modeling COVID-19 scenarios for the United States

Open access
IHME COVID-19 Forecasting Team, Reiner, Robert C., Barber, Ryan M., Collins, James K., Zheng, Peng, Adolph, Christopher, Albright, James, Antony, Catherine M., Aravkin, Aleksandr Y., Bachmeier, Steven D., Bang-Jensen, Bree, Bannick, Marlena S., Bloom, Sabina, Carter, Austin, Castro, Emma, Causey, Kate, Chakrabarti, Suman, Charlson, Fiona J., Cogen, Rebecca M., Combs, Emily, Dai, Xiaochen, Dangel, William James, Earl, Lucas, Ewald, Samuel B., Ezalarab, Maha, Ferrari, Alize J., Flaxman, Abraham, Frostad, Joseph Jon, Fullman, Nancy, Gakidou, Emmanuela, Gallagher, John, Glenn, Scott D., Goosmann, Erik A., He, Jiawei, Henry, Nathaniel J., Hulland, Erin N., Hurst, Benjamin, Johanns, Casey, Kendrick, Parkes J., Khemani, Apurva, Larson, Samantha Leigh, Lazzar-Atwood, Alice, LeGrand, Kate E., Lescinsky, Haley, Lindstrom, Akiaja, Linebarger, Emily, Lozano, Rafael, Ma, Rui, Månsson, Johan, Magistro, Beatrice, Herrera, Ana M. Mantilla, Marczak, Laurie B., Miller-Petrie, Molly K., Mokdad, Ali H., Morgan, Julia Deryn, Naik, Paulami, Odell, Christopher M., O’Halloran, James K., Osgood-Zimmerman, Aaron E., Ostroff, Samuel M., Pasovic, Maja, Penberthy, Louise, Phipps, Geoffrey, Pigott, David M., Pollock, Ian, Ramshaw, Rebecca E., Redford, Sofia Boston, Reinke, Grace, Rolfe, Sam, Santomauro, Damian Francesco, Shackleton, John R., Shaw, David H., Sheena, Brittney S., Sholokhov, Aleksei, Sorensen, Reed J. D., Sparks, Gianna, Spurlock, Emma Elizabeth, Subart, Michelle L., Syailendrawati, Ruri, Torre, Anna E., Troeger, Christopher E., Vos, Theo, Watson, Alexandrea, Watson, Stefanie, Wiens, Kirsten E., Woyczynski, Lauren, Xu, Liming, Zhang, Jize, Hay, Simon I., Lim, Stephen S., Murray, Christopher J. L.·2021·Nature Medicine

Published version of a preprint

Abstract

We use COVID-19 case and mortality data from 1 February 2020 to 21 September 2020 and a deterministic SEIR (susceptible, exposed, infectious and recovered) compartmental framework to model possible trajectories of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the effects of non-pharmaceutical interventions in the United States at the state level from 22 September 2020 through 28 February 2021. Using this SEIR model, and projections of critical driving covariates (pneumonia seasonality, mobility, testing rates and mask use per capita), we assessed scenarios of social distancing mandates and levels of mask use. Projections of current non-pharmaceutical intervention strategies by state—with social distancing mandates reinstated when a threshold of 8 deaths per million population is exceeded (reference scenario)—suggest that, cumulatively, 511,373 (469,578–578,347) lives could be lost to COVID-19 across the United States by 28 February 2021. We find that achieving universal mask use (95% mask use in public) could be sufficient to ameliorate the worst effects of epidemic resurgences in many states. Universal mask use could save an additional 129,574 (85,284–170,867) lives from September 22, 2020 through the end of February 2021, or an additional 95,814 (60,731–133,077) lives assuming a lesser adoption of mask wearing (85%), when compared to the reference scenario.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-1132-9

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Number of social distancing mandates by US state from 1 February 2020 to 22 September 2020. States are ordered by decreasing population size on the y axis. Source data
Fig. 1 Number of social distancing mandates by US state from 1 February 2020 to 22 September 2020. States are ordered by decreasing population size on the y axis. Source dataCC BY · PubMed Central
Fig. 2 Cumulative deaths from 1 February 2020 to 28 February 2021. The inset map displays the cumulative deaths under the plausible reference scenario on 28 February 2021. A light-yellow background separates the observed and predicted part of the time series, before and after 22 September 2020. The dashed vertical line identifies 3 November 2020. Solid lines represent boundary scenarios and dashed lines represent derivative scenarios. Numbers are the means and UIs for the plausible reference scenario on the highlighted dates. An asterisk indicates states with population centers exceeding 2 million persons. UIs are shown for only the plausible reference scenario. Source data
Fig. 2 Cumulative deaths from 1 February 2020 to 28 February 2021. The inset map displays the cumulative deaths under the plausible reference scenario on 28 February 2021. A light-yellow background separates the observed and predicted part of the time series, before and after 22 September 2020. The dashed vertical line identifies 3 November 2020. Solid lines represent boundary scenarios and dashed lines represent derivative scenarios. Numbers are the means and UIs for the plausible reference scenario on the highlighted dates. An asterisk indicates states with population centers exceeding 2 million persons. UIs are shown for only the plausible reference scenario. Source dataCC BY · PubMed Central
Fig. 3 Daily deaths from 1 February 2020 to 28 February 2021. The inset map displays the daily deaths under the plausible reference scenario on 28 February 2021. A light-yellow background separates the observed and predicted part of the time series, before and after 22 September 2020. The dashed vertical line identifies 3 November 2020. Solid lines represent boundary scenarios and dashed lines represent derivative scenarios. Numbers are the means and UIs for the plausible reference scenario on the highlighted dates. An asterisk indicates states with population centers exceeding 2 million persons. UIs are shown for only the plausible reference scenario. Source data
Fig. 3 Daily deaths from 1 February 2020 to 28 February 2021. The inset map displays the daily deaths under the plausible reference scenario on 28 February 2021. A light-yellow background separates the observed and predicted part of the time series, before and after 22 September 2020. The dashed vertical line identifies 3 November 2020. Solid lines represent boundary scenarios and dashed lines represent derivative scenarios. Numbers are the means and UIs for the plausible reference scenario on the highlighted dates. An asterisk indicates states with population centers exceeding 2 million persons. UIs are shown for only the plausible reference scenario. Source dataCC BY · PubMed Central
Fig. 4 Time series for values of Reffective by US state. Inset maps display the value of Reffective on 3 November 2020 and 28 February 2021; time series of Reffective are presented for each state as separate panels. A light-yellow background separates the observed and predicted part of the time series, before and after 22 September 2020. The dashed vertical line identifies 3 November 2020. An asterisk indicates states with population centers exceeding 2 million persons. Source data
Fig. 4 Time series for values of Reffective by US state. Inset maps display the value of Reffective on 3 November 2020 and 28 February 2021; time series of Reffective are presented for each state as separate panels. A light-yellow background separates the observed and predicted part of the time series, before and after 22 September 2020. The dashed vertical line identifies 3 November 2020. An asterisk indicates states with population centers exceeding 2 million persons. Source dataCC BY · PubMed Central
Extended Data Fig. 1 Estimated daily COVID-19 death rate (per 100,000 population) by state for all five scenarios. The inset map displays the estimated daily deaths from COVID-19 death per 100,000 population by state on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. Source data
Extended Data Fig. 1 Estimated daily COVID-19 death rate (per 100,000 population) by state for all five scenarios. The inset map displays the estimated daily deaths from COVID-19 death per 100,000 population by state on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. Source dataCC BY · PubMed Central
Extended Data Fig. 2 Estimated total hospital beds needed for COVID-19 patients by state from 01 February 2020 to 28 February, 2021, under the plausible reference scenario. The inset map displays the estimated peak number of all COVID-19 beds above capacity by state between 22 September 2020 and 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. Source data
Extended Data Fig. 2 Estimated total hospital beds needed for COVID-19 patients by state from 01 February 2020 to 28 February, 2021, under the plausible reference scenario. The inset map displays the estimated peak number of all COVID-19 beds above capacity by state between 22 September 2020 and 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. Source dataCC BY · PubMed Central
Extended Data Fig. 3 Estimated total ICU beds needed for COVID-19 patients by state from 01 February 2020 to 28 February 2021, under the plausible reference scenario. The inset map displays the estimated peak number of all ICU COVID-19 beds above capacity by state between 22 September 2020 and 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. Source data
Extended Data Fig. 3 Estimated total ICU beds needed for COVID-19 patients by state from 01 February 2020 to 28 February 2021, under the plausible reference scenario. The inset map displays the estimated peak number of all ICU COVID-19 beds above capacity by state between 22 September 2020 and 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. Source dataCC BY · PubMed Central
Extended Data Fig. 4 Estimated cumulative deaths from COVID-19 per 100,000 population from 01 February 2020 to 28 February 2021, by state, for all five scenarios. The inset map displays the estimated cumulative deaths per 100,000 population under the plausible reference scenario on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source data
Extended Data Fig. 4 Estimated cumulative deaths from COVID-19 per 100,000 population from 01 February 2020 to 28 February 2021, by state, for all five scenarios. The inset map displays the estimated cumulative deaths per 100,000 population under the plausible reference scenario on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source dataCC BY · PubMed Central
Extended Data Fig. 5 Estimated cumulative infections from SARS-CoV-2 from 01 February 2020 to 28 February 2021, by state, for all five scenarios. The inset map displays the estimated cumulative infections under the plausible reference scenario on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source data
Extended Data Fig. 5 Estimated cumulative infections from SARS-CoV-2 from 01 February 2020 to 28 February 2021, by state, for all five scenarios. The inset map displays the estimated cumulative infections under the plausible reference scenario on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source dataCC BY · PubMed Central
Extended Data Fig. 6 Estimated cumulative SARS-CoV-2 infection rate (per 100,000 population) by state, for all five scenarios. The inset map displays the estimated cumulative infections from COVID-19 per 100,000 population by state on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source data
Extended Data Fig. 6 Estimated cumulative SARS-CoV-2 infection rate (per 100,000 population) by state, for all five scenarios. The inset map displays the estimated cumulative infections from COVID-19 per 100,000 population by state on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source dataCC BY · PubMed Central
Extended Data Fig. 7 Estimated daily infections from SARS-CoV-2 from 01 February 2020 to 28 February 2021 by state, for all five scenarios. The inset map displays the estimated daily infections under the plausible reference scenario on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source data
Extended Data Fig. 7 Estimated daily infections from SARS-CoV-2 from 01 February 2020 to 28 February 2021 by state, for all five scenarios. The inset map displays the estimated daily infections under the plausible reference scenario on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source dataCC BY · PubMed Central
Extended Data Fig. 8 Estimated daily SARS-CoV-2 infection rate (per 100,000 population) by state, for all five scenarios. The inset map displays the estimated daily infections from COVID-19 per 100,000 population by state on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source data
Extended Data Fig. 8 Estimated daily SARS-CoV-2 infection rate (per 100,000 population) by state, for all five scenarios. The inset map displays the estimated daily infections from COVID-19 per 100,000 population by state on 28 February 2021. The light yellow background separates the observed and predicted part of the time series, before and after 21 September 2020. The dashed vertical line identifies 03 November 2020. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates highlighted. The UIs are shown only for the plausible reference scenario. Source dataCC BY · PubMed Central
Extended Data Fig. 9 Modeled SARS-CoV-2 infection prediction totals compared with survey-derived seroprevalence rates in select locations. Modeled SARS-CoV-2 infection prediction totals compared with survey-derived seroprevalence rates in select locations globally. The scatter plots show locations colour coded by country; horizontal bars are the 95% confidence interval in the modeled estimates. The inset violin plot of the measured seropositivity data show the predominantly low values seropositivity estimates (below 5%) recorded in this global sample. Source data
Extended Data Fig. 9 Modeled SARS-CoV-2 infection prediction totals compared with survey-derived seroprevalence rates in select locations. Modeled SARS-CoV-2 infection prediction totals compared with survey-derived seroprevalence rates in select locations globally. The scatter plots show locations colour coded by country; horizontal bars are the 95% confidence interval in the modeled estimates. The inset violin plot of the measured seropositivity data show the predominantly low values seropositivity estimates (below 5%) recorded in this global sample. Source dataCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 3

  1. Horton, R. The COVID-19 Catastrophe: What’s Gone Wrong and How to Stop it Happening Again. (John Wiley & Sons, 2020).
  2. GBD 2019 Population and Fertility Collaborators. Global, regional and national age-sex-specific fertility, mortality and population estimates, 1950–2019: a comprehensive demographic analysis for the global burden of disease study 2019. The Lancet (in press).
  3. GBD 2019 Diseases and injuries Collaborators. Global burden of 369 diseases and injuries, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet (in press).

Cited by

See all 556

Metadata

Authors
IHME COVID-19 Forecasting Team, Reiner, R. C., Barber, R. M., Collins, J. K., Zheng, P., Adolph, C., Albright, J., Antony, C. M., Aravkin, A. Y., Bachmeier, S. D., Bang-Jensen, B., Bannick, M. S., Bloom, S., Carter, A., Castro, E., Causey, K., Chakrabarti, S., Charlson, F. J., Cogen, R. M., Combs, E., Dai, X., Dangel, W. J., Earl, L., Ewald, S. B., Ezalarab, M., Ferrari, A. J., Flaxman, A., Frostad, J. J., Fullman, N., Gakidou, E., Gallagher, J., Glenn, S. D., Goosmann, E. A., He, J., Henry, N. J., Hulland, E. N., Hurst, B., Johanns, C., Kendrick, P. J., Khemani, A., Larson, S. L., Lazzar-Atwood, A., LeGrand, K. E., Lescinsky, H., Lindstrom, A., Linebarger, E., Lozano, R., Ma, R., Månsson, J., Magistro, B., Herrera, A. M. M., Marczak, L. B., Miller-Petrie, M. K., Mokdad, A. H., Morgan, J. D., Naik, P., Odell, C. M., O’Halloran, J. K., Osgood-Zimmerman, A. E., Ostroff, S. M., Pasovic, M., Penberthy, L., Phipps, G., Pigott, D. M., Pollock, I., Ramshaw, R. E., Redford, S. B., Reinke, G., Rolfe, S., Santomauro, D. F., Shackleton, J. R., Shaw, D. H., Sheena, B. S., Sholokhov, A., Sorensen, R. J. D., Sparks, G., Spurlock, E. E., Subart, M. L., Syailendrawati, R., Torre, A. E., Troeger, C. E., Vos, T., Watson, A., Watson, S., Wiens, K. E., Woyczynski, L., Xu, L., Zhang, J., Hay, S. I., Lim, S. S., & Murray, C. J. L.
Affiliations
  • University of Washington (US)
  • The University of Queensland (AU)
Venue
Nature Medicine
Published
2020-10-23
Volume
27
Issue
1
Pages
94-105
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3093610264
Cited by
556
References
56
Citations by year
2026: 17 · 2025: 25 · 2024: 61 · 2023: 84 · 2022: 134 · 2021: 210 · 2020: 25
FWCI
18.01
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders
  • National Science Foundation (2031096)
  • Bill and Melinda Gates Foundation
  • Institute for Health Metrics and Evaluation
Topics
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
  • Social Sciences › Sociology and Political Science › COVID-19 Prevention and Impact
Keywords
COVID-19 pandemic, SARS-CoV-2, SEIR model, epidemic projection, non-pharmaceutical interventions, masking, mortality, mobility, testing rates, epidemic resurgence, United States
MeSH terms
Physical Distancing, COVID-19, SARS-CoV-2, Health Policy, Humans, Models, Biological, Travel, United States, Epidemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modeling COVID-19 scenarios for the United States. https://app.cochat.ai/papers/10.1038/s41591-020-1132-9
The paper
IHME COVID-19 Forecasting Team, Reiner, R. C., Barber, R. M., Collins, J. K., Zheng, P., Adolph, C., Albright, J., Antony, C. M., Aravkin, A. Y., Bachmeier, S. D., Bang-Jensen, B., Bannick, M. S., Bloom, S., Carter, A., Castro, E., Causey, K., Chakrabarti, S., Charlson, F. J., Cogen, R. M., . . . Murray, C. J. L. (2021). Modeling COVID-19 scenarios for the United States. Nature Medicine. https://doi.org/10.1038/s41591-020-1132-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.